B3GAT2 and colorectal carcinoma: An example of the potential of this approach is provided by recent data suggesting that constitutional allelic variation in UDP-glucuronosyltransferase, a protein involved in the metabolism of irinotecan, may predict response and toxicity in patients with advanced CRC treated with capecitabine/irinotecan (Carlini et al, 2005).